3rd December 2018- Neurelis, Inc. issued an announcement, which is summarized as
Neurelis, Inc. announced the acquisition of Aegis Therapeutics, a San
Diego-based drug delivery technology company. Aegis Therapeutics’ proprietary
portfolio includes Intravail®, ProTek® and Hydrogel?,
three non-invasive drug delivery and stabilization technologies applicable to a
wide-range of molecules including therapeutic proteins, peptides, non-peptide
macromolecules and small molecules.
VALTOCO? (diazepam nasal spray), Neurelis’ lead product candidate, is a proprietary
formulation of diazepam incorporating the unique combination of a vitamin
E-based solution with Aegis’ Intravail® transmucosal absorption
enhancement technology. Intravail® has been shown to increase
absorption and reduce variability of drugs when incorporated in the
formulation, with no known negative impact on safety or tolerability. Neurelis
anticipates FDA approval and commercial launch of VALTOCO in 2019.
Original website Link: